Role of CD47 as a Marker of Self on Red Blood Cells

2000/06/16 by Per-Arne Oldenborg, Per‐Arne Oldenborg, Alex Zheleznyak +5 · 38 citations
Medicine · Immunology and Microbiology · #Erythrocyte Function and Pathophysiology #Phagocytosis and Immune Regulation #Blood groups and transfusion

paper · doi:10.1126/science.288.5473.2051

Abstract

The immune system recognizes invaders as foreign because they express determinants that are absent on host cells or because they lack "markers of self" that are normally present. Here we show that CD47 (integrin-associated protein) functions as a marker of self on murine red blood cells. Red blood cells that lacked CD47 were rapidly cleared from the bloodstream by splenic red pulp macrophages. CD47 on normal red blood cells prevented this elimination by binding to the inhibitory receptor signal regulatory protein alpha (SIRPalpha). Thus, macrophages may use a number of nonspecific activating receptors and rely on the presence or absence of CD47 to distinguish self from foreign. CD47-SIRPalpha may represent a potential pathway for the control of hemolytic anemia.

Cited by

• CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
• Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
• Tumor Abnormality-Oriented Nanomedicine Design
• CD47 inhibits phagocytosis through Vav dephosphorylation
• Therapeutic modulation of APP-CD74 axis can activate phagocytosis of TAMs in GBM
• Targeting tumor-associated macrophages to synergize tumor immunotherapy
• An Apoptotic ‘Eat Me’ Signal: Phosphatidylserine Exposure
• Niche signals and transcription factors involved in tissue-resident macrophage development
• The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
• Functions and development of red pulp macrophages
• P66 is a bacterial mimic of CD47 that binds the anti-phagocytic receptor SIRPα and facilitates macrophage evasion by <i>Borrelia burgdorferi</i>
• Transfusion management in the era of magrolimab (<scp>Hu5F9‐G4</scp>), an anti‐<scp>CD47</scp> monoclonal antibody therapy
• Cues for apoptotic cell engulfment: eat-me, don't eat-me and come-get-me signals
• Shape effects of filaments versus spherical particles in flow and drug delivery. [europepmc]
• Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. [europepmc]
• CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. [europepmc]
• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. [europepmc]
• The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. [europepmc]
• Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. [europepmc]
• Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. [europepmc]
• Apoptotic cell clearance: basic biology and therapeutic potential. [europepmc]
• State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. [europepmc]
• Alternative 3' UTRs act as scaffolds to regulate membrane protein localization. [europepmc]
• CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. [europepmc]
• CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. [europepmc]
• Erythrocyte-Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization. [europepmc]
• Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. [europepmc]
• Cell Membrane Coating Nanotechnology. [europepmc]
• CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development. [europepmc]
• CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. [europepmc]
• First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. [europepmc]
• How macrophages deal with death. [europepmc]
• Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. [europepmc]
• Phagocytosis checkpoints as new targets for cancer immunotherapy. [europepmc]
• The clearance of dead cells by efferocytosis. [europepmc]
• The CD47-SIRPα Immune Checkpoint. [europepmc]
• Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. [europepmc]
• Targeting tumor-associated macrophages to synergize tumor immunotherapy. [europepmc]

Related

• Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
• CD47 inhibits phagocytosis through Vav dephosphorylation
• CD45: A Critical Regulator of Signaling Thresholds in Immune Cells
• CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
• MACROPHAGE RECEPTORS AND IMMUNE RECOGNITION